Одна из главных задач Life4me+ — предотвращение новых случаев заражения ВИЧ-инфекцией и другими ИППП, гепатитом C и туберкулезом.

Приложение позволяет установить анонимную связь между врачами и ВИЧ-позитивными людьми, дает возможность организовать своевременный прием ваших медикаментов, получать замаскированные напоминания о них.

11722

Специализированная клиническая информация о коронавирусе COVID-19

Информация постоянно обновляется. Последнее обновление

Просмотрите FAQs о COVID-19 и людях, живущих с ВИЧ

Просмотр FAQs
Coronavirus Innovation Map
Rights in the time of COVID-19. Lessons from HIV for an effective, community-led response.
What People Living with HIV Need to Know about HIV and COVID-19
EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) and SARS-CoV-2 vaccine advice for adults living with HIV
SARS-CoV-2 /COVID-19 - Antiviral and immunomodulatory treatment considerations
Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium
Inpatient guidance for treatment of COVID-19 in adults and children (University of Michigan, USA)
Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19 (Италия, Ломбардия)
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine)
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
“Recovery” clinical trial for COVID-19 treatments
“Solidarity” clinical trial for COVID-19 treatments
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
NIH Final report confirms remdesivir benefits for COVID-19
WHO Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
Remdesivir for the Treatment of Covid-19 — Final Report
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Increased efficacy with longer inter-dose interval. Protection of over 70% starting after a first dose. First indication of reduction in disease transmission of up to 67%
Sputnik V COVID-19 vaccine candidate appears safe and effective
Johnson & Johnson: Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
EATG (European Aids Treatment Group) statement on the evolving COVID-19 pandemic
The Position of Correlation-European Harm Reduction Network and EHRA on the Continuity of Harm Reduction Services During the COVID-19 Crisis
Human Rights Dimensions of COVID-19 Response
COVID-19: Sex Workers Need Immediate Financial Support and Protection
COVID19: “Staying Home” Not an Option for People Experiencing Homelessness
Coronavirus: Healthcare and human rights of people in prison

Просмотрите FAQs о COVID-19 и людях, живущих с ВИЧ

Просмотр FAQs

Если у вас есть вопросы или комментарии по поводу ВИЧ и COVID-19, сообщите нам [email protected]